700363-47-9

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 294862-91-2 (3S,4S)-4-benzyloxypentane-1,3-diol 
• 294863-22-2 (-)-(3S,4S)-4-(benzyloxy)-3-(tert-butyldimethylsilyloxy)pentan-1-ol 
• 148409-86-3 methyl (3S,4S)-4-benzyloxy-3-(tert-butyldimethylsilyloxy)pentanoate 

Downstream Products

• 294863-24-4 1-[(2S,3R)-2-benzyloxy-5-hydroxy-3-pentyl]imidazole-4-carboxamide 
• 294863-25-5 1-[(2S,3R)-2-benzyloxy-5-methylsulfonyloxy-3-pentyl]imidazole-4-carboxamide 
• 294862-80-9 1-[(2S,3R)-2-benzyloxy-5-(tert-butyldimethylsilyloxy)-3-pentyl]imidazole-4-carboxamide 
• 335022-98-5 1-[(2S,3R)-2-benzyloxy-5-(2-naphthyloxy)-3-pentyl]imidazole-4-carboxamide 

Relevant academic research and scientific papers

Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors

We disclose optimization efforts based on the novel non-nucleoside adenosine deaminase (ADA) inhibitor, 4 (Ki = 680 nM). Structure-based drug design utilizing the crystal structure of the 4/ADA complex led to discovery of 5 (Ki = 11

Heterocyclic compound, composition and method for inhibiting adenosine deaminase

Heterocyclic compounds of the following formula: wherein B is ?[wherein R1is hydrogen or lower alkyl; R2is hydrogen or lower alkyl; and X is hydrogen or hydroxy protective group], lower alkanoyl or hydroxyimino(lower)alkyl A is lower